• Losartan Workflows for Vascular and Renal Research

  2026-08-13

  Losartan provides a practical AT1 receptor perturbation strategy for connecting angiotensin II signaling with vascular remodeling, blood-pressure phenotypes, and diabetic nephropathy mechanisms. This workflow-focused guide shows how to select concentrations, pair receptor blockade with matrix and cell-cycle readouts, and troubleshoot experiments across cell and animal models.

• T-5224: C-Fos/AP-1 Inhibition Workflows

  2026-08-12

  T-5224 provides a selective way to test whether c-Fos/c-Jun AP-1 activity drives inflammatory, osteoclastogenic, or neuroinflammatory outputs. This practical guide covers formulation, cell-based workflows, assay selection, troubleshooting, and the cautious extension of arthritis research into trigeminal pain biology.

• Azilsartan Medoxomil Monopotassium in Translation

  2026-08-12

  A mechanistic and translational framework for using Azilsartan medoxomil monopotassium (TAK 491) in AT1 receptor, blood pressure, cardiovascular, and renal research.

• Z-DEVD-FMK: A Caspase-3 Inhibitor Workflow

  2026-08-11

  Z-DEVD-FMK combines cell-permeable, irreversible inhibition of caspase-3 and related caspases with measurable calpain pathway effects. This article translates that profile into practical apoptosis assays, neuroprotection workflows, and a mechanistic antiviral application based on SADS-CoV research.

• Deracoxib in Canine Inflammation and Cancer Models

  2026-08-10

  Deracoxib is a selective COX-2 inhibitor that connects prostaglandin biology with canine pain, inflammation, and tumor-cell assays. This evidence-led guide explains how to select concentrations, interpret apoptosis data, and avoid overextending in vitro findings.

• Sodium Orthovanadate in Insulin Signaling Research

  2026-08-09

  Sodium Orthovanadate (Na3VO4) is more than a routine phosphatase additive: it is a strategic tool for preserving phosphorylation-dependent evidence in metabolic signaling studies. This thought-leadership guide connects its reversible, competitive inhibition profile with insulin-resistance research, including the PI-3K/AKT/GLUT4 findings reported for trelagliptin-treated adipocytes.

• N2703 for Adipose-Neural Cardiac Assays

  2026-08-08

  Use 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) as a controlled exploratory perturbation in stem cell-derived neuron–cardiomyocyte–adipocyte models. This workflow emphasizes concentration control, orthogonal electrophysiology and calcium readouts, and pathway-specific controls so researchers can distinguish neuronal stimulation from nonspecific toxicity.

• Tacalcitol Sensitizes CRC Cells to 5-FU

  2026-08-07

  The reference study identifies a VDR–CDKN1A/p21 pathway through which tacalcitol lowers thymidylate synthase and enhances 5-fluorouracil activity in HT-29 colorectal cancer cells. Its findings connect vitamin D receptor signaling, epithelial differentiation markers, and chemotherapy response while suggesting VDR and CaSR as candidate stratification markers.

• Fosinopril Sodium: Advanced ACE Inhibition for Hypertension

  2026-08-07

  Fosinopril sodium is a third-generation ACE inhibitor prodrug with high specificity and dual renal-hepatic elimination. It enables precise blood pressure reduction and robust modeling in hypertension research. Its validated pharmacokinetics and unique zinc ion binding profile distinguish it within cardiovascular studies.

• Losartan-Based Hydrogel Remodels Tumor Mechanics to Enhance

  2026-08-06

  Hou et al. (2024) introduce a losartan-based nanocomposite hydrogel that overcomes chemo-immunotherapy resistance by targeting the tumor mechanical microenvironment. Their work demonstrates how modifying extracellular matrix stiffness with sustained losartan delivery synergistically improves checkpoint blockade efficacy, offering a mechanistic rationale for new combination regimens against refractory tumors.

• Deracoxib: Selective COX-2 Inhibitor in Inflammation Researc

  2026-08-06

  Deracoxib is a selective COX-2 inhibitor with proven anti-inflammatory and antitumor effects in canine models. It demonstrates cell type-specific cytotoxicity, modulates the NO pathway, and enhances chemotherapy efficacy. This article outlines Deracoxib’s biological rationale, mechanism, evidence, and optimal use in pain and inflammation research.

• Silybin A in Silymarin: Optimized Workflows for Liver Diseas

  2026-08-05

  Silybin A, the flagship flavonolignan of Silymarin, offers targeted advantages for liver disease and metabolic research through potent antioxidant and hepatoprotective actions. This article details advanced experimental protocols, troubleshooting tips, and comparative workflow insights leveraging high-purity Silybin A from APExBIO, enabling reproducibility and translational impact across immunology, metabolism, and cancer biology studies.

• WP1066, JAK2/STAT3 Inhibitor: Protocols & New Regenerative U

  2026-08-05

  WP1066, a cell-permeable JAK2/STAT3 inhibitor from APExBIO, has rapidly evolved from a mainstay in oncology research to a tool for dissecting macrophage-driven bone regeneration. This guide bridges optimized cancer protocols and innovative tissue repair applications, offering practical workflow enhancements and troubleshooting grounded in recent landmark studies.

• Azilsartan (TAK-536) in Renin-Angiotensin System Research

  2026-08-04

  Azilsartan (TAK-536) is a potent AT1 receptor antagonist enabling precision dissection of the renin-angiotensin system in cardiovascular and neuroinflammation models. Leverage high-purity Azilsartan from APExBIO to optimize reactive astrocyte–microglia workflows, troubleshoot specificity, and advance mechanistic insights into RAS–SIRT3 signaling.

• Deracoxib in Veterinary Oncology: Beyond COX-2 Inhibition

  2026-08-04

  Explore the advanced role of Deracoxib, a selective COX-2 inhibitor, in veterinary oncology and inflammation research. This article uniquely examines its apoptosis-modulating properties and synergy with chemotherapy, providing strategic guidance for translational assay design.

449 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page